A Prospective Clinical Trail of Corticosteroids in Combination with Mycophenolate Mofetil Dispersible Tablets and Tacrolimus for the Induction Treatment of Lupus Nephritis
HU Wei-xin,CHEN Ying-hua,LIU Zheng-zhao,ZHANG Hai-tao,CHEN Hui-ping,ZENG Cai-hong,ZHANG Li-hua,LIU Zhi-hong
DOI: https://doi.org/10.3969/j.issn.1006-298x.2011.04.001
2011-01-01
Abstract:Objective:To prospectively observe the clinical efficacy and safety of corticosteroids in combination with mycophenolate mofetil dispersible tablets(Cicopin~,MMF,Hangzhou Zhongmei Huadong pharmaceutical Co,Ltd) and tacrolimus(FK506,Hangzhou Zhongmei Huadong pharmaceutical Co,Ltd)(multi-target group) in the induction treatment for lupus nephritis(LN).Methodology:Seventy-nine patients with biopsy confirmed class IV,V+IV and V+III LN were randomly assigned to either multi-target group [n=45,39 females,6 males,mean age(25.1±9.3) years] or intravenous cyclophosphamide pulse therapy(IV-CYC) [n=34,30 females,4 males,mean age(30.4±8.9) years].All patients received intravenous methylprednisolone pulse therapy followed by oral prednisone.In multi-target group,the dose of MMF and FK506 was adjusted based on the blood level with the MPA-AUC0～12h level of 20～30 mg o h/L and FK506 trough level 4～7 ng/ml.In IV-CYC group,CYC was given in a dose 0.5～0.75 g/m2BSA monthly.The induction period was 6months to 9 months according to the responses on the therapy.The primary efficacy parameter was complete remission rate(defined as urine protein 0.4 g/24h,serum albumin ≥35 g/l,normal serum creatinine and no extra-renal activity),the secondary parameters were partial remission rate(defined as urinary protein less than the base value of 50% or more,and urine protein 3.5 g/24h,serum albumin ≥30 g/l,and serum creatinine stable) and incidence of adverse reactions.The clinical efficacy and adverse events were compared between two groups.Results:The baseline clinical and histological classes had no significant differences between multi-target group and IV-CYC group.The accumulated complete remission rate of multi-target group was significantly higher than that of IV-CYC group(P0.05) during the induction period.At 6months and 9 months,the complete remission rate was 53.3% and 62.2% respectively in the multi-target group,and 29.4% and 42.6%,in IV-CYC group respectively.Also,multi-target therapy showed much higher complete remission rate than IV-CYC therapy for class V+IV(50.0% vs 16.7%,P0.05) and class V+III(54.5% vs 22.2 %,P0.05).In class IV LN,no difference of the remission rate was found between the two groups.The incidence of adverse events in the multi-target group was much lower than that in the IV-CYC group(31.1% vs 70.6%,P0.01),the major adverse events were new-onset hypertension(11.1%) and herpes zoster(6.7%) in the multi-target group;while gastrointestinal reactions(23.5%),leukopenia(13.7%) and skin infections(8.8%) in the IV-CYC group.Three patients(2 in multi-target group and 1 in IV-CYC group) complicated with pulmonary infection,but none died.Conclusion:The multi-target therapy,which is composed of corticosteroids with Cicopin and tacrolimus,showed more effective than intravenous CYC pulse therapy in inducing remission of lupus nephritis,especially class V+IV,and had a more favorable safety.However,multi-center clinical trials are encouraged to evaluate the clinical efficacy and the impact on long-term survival for lupus nephritis.